Literature DB >> 21488084

Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein.

Hoa A Lam1, Nanping Wu, Ingrid Cely, Rachel L Kelly, Sindalana Hean, Franziska Richter, Iddo Magen, Carlos Cepeda, Larry C Ackerson, Wendy Walwyn, Eliezer Masliah, Marie-Françoise Chesselet, Michael S Levine, Nigel T Maidment.   

Abstract

Overexpression or mutation of α-synuclein (α-Syn), a protein associated with presynaptic vesicles, causes familial forms of Parkinson's disease in humans and is also associated with sporadic forms of the disease. We used in vivo microdialysis, tissue content analysis, behavioral assessment, and whole-cell patch clamp recordings from striatal medium-sized spiny neurons (MSSNs) in slices to examine dopamine transmission and dopaminergic modulation of corticostriatal synaptic function in mice overexpressing human wild-type α-Syn under the Thy1 promoter (α-Syn mice). Tonic striatal extracellular dopamine and 3-methoxytyramine levels were elevated in α-Syn mice at 6 months of age, prior to any reduction in total striatal tissue content, and were accompanied by an increase in open-field activity. Dopamine clearance and amphetamine-induced dopamine efflux were unchanged. The frequency of MSSN spontaneous excitatory postsynaptic currents (sEPSCs) was lower in α-Syn mice. Amphetamine reduced sEPSC frequency in wild types (WTs) but produced no effect in α-Syn mice. Furthermore, whereas quinpirole reduced and sulpiride increased sEPSC frequency in WT mice, they produced the opposite effects in α-Syn mice. These observations indicate that overexpression of α-Syn alters dopamine efflux and D2 receptor modulation of corticostriatal glutamate release at a young age. At 14 months of age, the α-Syn mice presented with significantly lower striatal tissue dopamine and tyrosine hydroxylase content relative to WT littermates, accompanied by an L-DOPA-reversible sensory motor deficit. Together, these data further validate this transgenic mouse line as a slowly progressing model of Parkinson's disease and provide evidence for early dopamine synaptic dysfunction prior to loss of striatal dopamine.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21488084      PMCID: PMC4755488          DOI: 10.1002/jnr.22611

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  58 in total

1.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

2.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch.

Authors:  J M George; H Jin; W S Woods; D F Clayton
Journal:  Neuron       Date:  1995-08       Impact factor: 17.173

3.  Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway.

Authors:  Nanping Wu; Prasad R Joshi; Carlos Cepeda; Eliezer Masliah; Michael S Levine
Journal:  J Neurosci Res       Date:  2010-06       Impact factor: 4.164

Review 4.  Genetic mouse models of Parkinson's disease The state of the art.

Authors:  Iddo Magen; Marie-Françoise Chesselet
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

5.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.

Authors:  T G Hastings; D A Lewis; M J Zigmond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

6.  Dopamine selects glutamatergic inputs to neostriatal neurons.

Authors:  J Flores-Hernández; E Galarraga; J Bargas
Journal:  Synapse       Date:  1997-02       Impact factor: 2.562

7.  Olfactory deficits in mice overexpressing human wildtype alpha-synuclein.

Authors:  Sheila M Fleming; Nicole A Tetreault; Caitlin K Mulligan; Ché B Hutson; Eliezer Masliah; Marie-Françoise Chesselet
Journal:  Eur J Neurosci       Date:  2008-07       Impact factor: 3.386

8.  Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.

Authors:  Edward Rockenstein; Margaret Mallory; Makoto Hashimoto; David Song; Clifford W Shults; Ingrid Lang; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2002-06-01       Impact factor: 4.164

9.  Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein.

Authors:  Lixin Wang; Sheila M Fleming; Marie-Françoise Chesselet; Yvette Taché
Journal:  Neuroreport       Date:  2008-05-28       Impact factor: 1.837

10.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors:  Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

View more
  73 in total

1.  Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.

Authors:  L Wang; I Magen; P-Q Yuan; S R Subramaniam; F Richter; M-F Chesselet; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-07-11       Impact factor: 3.598

2.  Synj1 haploinsufficiency causes dopamine neuron vulnerability and alpha-synuclein accumulation in mice.

Authors:  Ping-Yue Pan; Patricia Sheehan; Qian Wang; Xinyu Zhu; Yuanxi Zhang; Insup Choi; Xianting Li; Jacqueline Saenz; Justin Zhu; Jing Wang; Farida El Gaamouch; Li Zhu; Dongming Cai; Zhenyu Yue
Journal:  Hum Mol Genet       Date:  2020-08-11       Impact factor: 6.150

3.  Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.

Authors:  Martin Lundblad; Mickael Decressac; Bengt Mattsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

4.  Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Authors:  Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

5.  Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.

Authors:  Emily R Dirr; Osunde R Ekhator; Rachel Blackwood; John G Holden; Eliezer Masliah; Patrick J Schultheis; Sheila M Fleming
Journal:  Behav Brain Res       Date:  2018-02-03       Impact factor: 3.332

6.  Exogenous α-Synuclein Monomers Alter Dopamine Metabolism in Murine Brain.

Authors:  Adriana Wawer; Ilona Joniec-Maciejak; Anna Sznejder-Pachołek; Joanna Schwenkgrub; Agnieszka Ciesielska; Dagmara Mirowska-Guzel
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

7.  An unexpected improvement in spatial learning and memory ability in alpha-synuclein A53T transgenic mice.

Authors:  Qi Liu; YuYu Xu; WenPing Wan; ZeGang Ma
Journal:  J Neural Transm (Vienna)       Date:  2017-12-07       Impact factor: 3.575

8.  Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.

Authors:  Laura M Grant; Franziska Richter; Julie E Miller; Stephanie A White; Cynthia M Fox; Chunni Zhu; Marie-Francoise Chesselet; Michelle R Ciucci
Journal:  Behav Neurosci       Date:  2014-04       Impact factor: 1.912

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

10.  Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.

Authors:  Ulrika H Julku; Anne E Panhelainen; Saija E Tiilikainen; Reinis Svarcbahs; Anne E Tammimäki; T Petteri Piepponen; Mari H Savolainen; Timo T Myöhänen
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.